Artificial intelligence can improve the effectiveness and affordability of how healthcare is delivered, attendees at the 2024 ...
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), ...
Health-care companies were flat, hovering near all-time highs amid optimism about the biotech and obesity-drug niches. In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people ...
Although head-to-head results on tolerability were missing from the company’s data release, Eli Lilly and Co. said its U.S. FDA-approved weight-loss drug Zepbound (tirzepatide) beat the also-cleared ...
With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...
People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...
The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...
Adults who take Zepbound lose more weight than those who take competitor weight loss drug Wegovy, according to new clinical ...